2023 saw the approval of the first single-dose RSV vaccine and monoclonal antibody treatments, offering unprecedented protection against severe respiratory syncytial virus infection in infants and high-risk populations. These advancements address a leading cause of infant hospitalization and mortality worldwide, including among American Indian and Alaska Native communities disproportionately affected by RSV. The new prophylactics reduce ICU admissions and hospital stays, marking a major public health milestone.